Please provide your email address to receive an email when new articles are posted on . Tremfya is an interleukin-23 inhibitor being evaluated for the treatment of psoriatic arthritis.

Psoriatic arthritis (PsA) is a long-lasting condition that affects the joints in people who have a skin condition called psoriasis. When you have PsA, your immune system mistakenly attacks your own ...

Arthritis is one of the most common chronic conditions affecting millions of people worldwide. Yet, many fail to recognize its early warning signs, dismissing them as minor aches or stiffness. By the ...

Delays in diagnosing and treating psoriatic arthritis – a common inflammatory disorder affecting 112 in every 100,000 adults – are causing irreparable damage to people’s health. This damage could be ...

Higher levels of inflammation and increased scores for radiographic sacroiliitis are linked to structural damage in the spine ...

TREMFYA ® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results ...